FDA inspection
GlaxoSmithKline, LLC.: FDA inspection ending Jun 20, 2023
FDA inspection 1211050 · No Action Indicated (NAI) · Conshohocken, PA
Key facts
| Inspection ID | 1211050 |
|---|---|
| Firm | GlaxoSmithKline, LLC. |
| FEI number | 3004055938 |
| Address | 893 Schuylkill River Rd Bldg 40 |
| City | Conshohocken |
| State | PA |
| ZIP | 19428 |
| Country | United States |
| Fiscal year | 2023 |
| Inspection end date | Jun 20, 2023 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data